文献速递MDS 与骨髓增殖性肿瘤

分泌型突变钙网蛋白作为骨髓增殖性肿瘤中的异常细胞因子

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2023-01-01

该研究发现CALR外显子9移码突变产生的突变钙网蛋白可被分泌入血,在患者血浆中可达160 ng/mL(均值25.64 ng/mL),并与可溶性转铁蛋白受体1(sTFR1)形成复合物延长半衰期;该复合物仍可激活血小板生成素受体(TpoR),且一个细胞产生的突变CALR可反式作用于靶细胞TpoR,同时携带TpoR与突变CALR的细胞对外源突变CALR超敏。

要点

  • 突变CALR蛋白可分泌至患者血浆,水平最高达160 ng/mL,均值25.64 ng/mL。
  • 血浆突变CALR与sTFR1结合,sTFR1作为载体蛋白延长突变CALR半衰期。
  • CALR-sTFR1复合物仍具有激活TpoR的功能,可反式作用于靶细胞。

核心结论

  • 伴CALR外显子9移码突变的骨髓增殖性肿瘤中,突变CALR蛋白可分泌入血并与sTFR1形成复合物,仍能激活TpoR,提示钙网蛋白经体细胞突变可转变为异常细胞因子。

研究设计与样本

  • 研究检测了患者血浆中的突变CALR蛋白,并在细胞系及CALR突变患者原代巨核祖细胞中检测重组突变CALR与TpoR的相互作用及功能。

主要发现

  • 患者血浆中突变CALR水平最高达160 ng/mL,均值25.64 ng/mL。
  • 血浆突变CALR与可溶性转铁蛋白受体1(sTFR1)形成复合物,sTFR1作为载体蛋白延长突变CALR半衰期。
  • 重组突变CALR蛋白可结合并激活细胞系及CALR突变患者原代巨核祖细胞中的TpoR,驱动不依赖血小板生成素的集落形成。
  • CALR-sTFR1复合物仍具有激活TpoR的功能;生物发光共振能量转移 assay 显示一个细胞产生的突变CALR可与靶细胞TpoR发生特异性反式相互作用。
  • 与仅携带TpoR的细胞相比,同时携带TpoR与突变CALR的细胞对外源突变CALR超敏,可对与患者血浆相似水平的突变CALR产生反应。

关键数值与推荐

  • 患者血浆突变CALR水平最高达160 ng/mL,均值25.64 ng/mL。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact with and activate the thrombopoietin receptor (TpoR/MPL) in the same cell. We report that mutant CALR proteins are secreted and can be found in patient plasma at levels up to 160 ng/mL, with a mean of 25.64 ng/mL. Plasma mutant CALR is found in complex with soluble transferrin receptor 1 (sTFR1) that acts as a carrier protein and increases mutant CALR half-life. Recombinant mutant CALR proteins bound and activated the TpoR in cell lines and primary megakaryocytic progenitors from patients with mutated CALR in which they drive thrombopoietin-independent colony formation. Importantly, the CALR-sTFR1 complex remains functional for TpoR activation. By bioluminescence resonance energy transfer assay, we show that mutant CALR proteins produced in 1 cell can specifically interact in trans with the TpoR on a target cell. In comparison with cells that only carry TpoR, cells that carry both TpoR and mutant CALR are hypersensitive to exogenous mutant CALR proteins and respond to levels of mutant CALR proteins similar to those in patient plasma. This is consistent with CALR-mutated cells that expose TpoR carrying immature N-linked sugars at the cell surface. Thus, secreted mutant CALR proteins will act more specifically on the MPN clone. In conclusion, a chaperone, CALR, can turn into a rogue cytokine through somatic mutation of its encoding gene.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pecquet C, Papadopoulos N, Balligand T, et al. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms. Blood. 2023. PMID: 36356299. doi:10.1182/blood.2022016846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。